{"nctId":"NCT00620282","briefTitle":"The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus","startDateStruct":{"date":"2008-02"},"conditions":["Diabetes","Diabetes Mellitus, Type 2"],"count":49,"armGroups":[{"label":"Lira 1.8","type":"EXPERIMENTAL","interventionNames":["Drug: liraglutide"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo"]},{"label":"Glimepiride","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: glimepiride"]}],"interventions":[{"name":"liraglutide","otherNames":[]},{"name":"placebo","otherNames":[]},{"name":"glimepiride","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Type 2 diabetes\n* Diet and lifestyle changes or metformin monotherapy for at least three months\n* HbA1c (glycosylated haemoglobin) 6.5-9.0% (both inclusive)\n* Body Mass Index (BMI) less than or equal to 40 kg/m\\^2\n\nExclusion Criteria:\n\n* Previous treatment with insulin (except for short term treatment with insulin in connection with intercurrent illness, at the discretion of the Investigator)\n* Previous treatment with glucagon-like peptide-1 (GLP-1) analogues/mimetics, including treatment in a clinical trial\n* Treatment with any oral hypoglycaemic agents other than metformin in a period of 3 months prior to screening\n* Current smoker or history of smoking within 6 months prior to screening\n* Evidence of overt cardiovascular disease (documented coronary heart disease, class II-IV congestive heart failure, cerebrovascular disease, or peripheral vascular disease)\n* Abnormal, clinically significant exercise stress electrocardiogram (ECG) test, as judged by the Investigator\n* Known retinopathy or maculopathy requiring acute treatment, as judged by the Investigator\n* Known autonomic neuropathy, as judged by the Investigator\n* Initiation or change (dose or treatment regimen) in concomitant blood pressure-lowering or lipid-lowering medication within 4 weeks prior to screening\n* Systolic blood pressure more than or equal to 140 mmHg and/or diastolic blood pressure more than or equal to 90 mmHg","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Acetylcholine (ACh)-Mediated Forearm Blood Flow (FBF)","description":"Assessed endothelial function by measuring the change in ACh-mediated FBF at euglycemia (90 mg/dL) using forearm venous occlusion plethysmography (VOP) technique. Unit of Measure refers to volume of blood (mL) per 100 mL of forearm tissue per minute.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.244","spread":"2.551"},{"groupId":"OG001","value":"-3.187","spread":"2.758"},{"groupId":"OG002","value":"2.164","spread":"2.568"}]}]}]},{"type":"SECONDARY","title":"Change in Sodium Nitroprusside (SNP)-Mediated Forearm Blood Flow (FBF)","description":"Assessed endothelial function by measuring the change in SNP-mediated FBF at euglycemia (90 mg/dL) using forearm venous occlusion plethysmography (VOP) technique. Unit of Measure refers to volume of blood (mL) per 100 mL of forearm tissue per minute.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.455","spread":"2.681"},{"groupId":"OG001","value":"-1.044","spread":"2.893"},{"groupId":"OG002","value":"2.746","spread":"2.67"}]}]}]},{"type":"SECONDARY","title":"Change in HbA1c (Glycosylated Haemoglobin A1c)","description":"Percentage point change in HbA1c","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.629","spread":"0.109"},{"groupId":"OG001","value":"-0.094","spread":"0.121"},{"groupId":"OG002","value":"-0.552","spread":"0.112"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Plasma Glucose (FPG)","description":"Change in FPG","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-41.672","spread":"3.643"},{"groupId":"OG001","value":"-6.067","spread":"4.079"},{"groupId":"OG002","value":"-32.019","spread":"3.708"}]}]}]},{"type":"SECONDARY","title":"Change in Mean Postprandial Glucose (PPG) Based on Self-measured 7-point Plasma Glucose Profiles","description":"The 7-point profile included plasma glucose measurements at the following time points: before each main meal (breakfast, lunch and dinner), 90 minutes after the start of each main meal (breakfast, lunch and dinner) and at bedtime.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-32.175","spread":"9.104"},{"groupId":"OG001","value":"-20.304","spread":"10.619"},{"groupId":"OG002","value":"-35.99","spread":"8.673"}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.821","spread":"0.455"},{"groupId":"OG001","value":"-0.293","spread":"0.486"},{"groupId":"OG002","value":"1.038","spread":"0.441"}]}]}]},{"type":"SECONDARY","title":"Fasting Lipid Profile - Change in Total Cholesterol (TC)","description":"Change in TC","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.006","spread":"5.274"},{"groupId":"OG001","value":"4.243","spread":"5.597"},{"groupId":"OG002","value":"0.094","spread":"5.239"}]}]}]},{"type":"SECONDARY","title":"Fasting Lipid Profile - Change in LDL-C","description":"Change in LDL-C","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.243","spread":"4.294"},{"groupId":"OG001","value":"-2.459","spread":"4.551"},{"groupId":"OG002","value":"-1.529","spread":"4.275"}]}]}]},{"type":"SECONDARY","title":"Fasting Lipid Profile - Change in HDL-C","description":"Change in HDL-C","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.393","spread":"1.053"},{"groupId":"OG001","value":"0.562","spread":"1.133"},{"groupId":"OG002","value":"1.116","spread":"1.074"}]}]}]},{"type":"SECONDARY","title":"Fasting Lipid Profile - Change in Triglycerides (TG)","description":"Change in TG","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.163","spread":"13.471"},{"groupId":"OG001","value":"28.546","spread":"14.282"},{"groupId":"OG002","value":"-4.377","spread":"13.399"}]}]}]},{"type":"SECONDARY","title":"Biomarkers of Cardiovascular Risk - Change in TNF-alpha","description":"Change in TNF-alpha","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.024","spread":"0.232"},{"groupId":"OG001","value":"0.397","spread":"0.25"},{"groupId":"OG002","value":"-0.0050","spread":"0.231"}]}]}]},{"type":"SECONDARY","title":"Haematology and Biochemistry Tests - Number of Subjects With Blood Urea Nitrogen (BUN) Values Outside Reference Range","description":"Number of subjects with serum BUN values outside reference range at Week 0 and Week 12, respectively. Reference range: Female (lower value 6.000 mg/dL, upper value 21.000 mg/dL) Male (lower value 8.000 mg/dL, upper value 25.000 mg/dL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Haematology and Biochemistry Tests - Number of Subjects With Creatinine Values Outside Reference Range","description":"Number of subjects with serum creatinine values outside reference range at Week 0 and Week 12, respectively. Reference range: Female (lower value 0.600 mg/dL, upper value 1.100 mg/dL) Male (lower value 0.800 mg/dL, upper value 1.300 mg/dL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Hypoglycaemic Episodes","description":"Total number of hypoglycaemic episodes occurring from week 0 to week 12. Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself and either plasma glucose was below 56 mg/dL or symptoms were reversed after food intake or glucagon/intravenous glucose administration. Minor if subject was able to treat her/himself and plasma glucose was below 56 mg/dL. Symptoms only if subject was able to treat her/himself and with no plasma glucose measurement or plasma glucose higher than or equal to 56 mg/dL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":16},"commonTop":["Dyspepsia","Nausea","Vomiting","Abdominal pain upper","Diarrhoea"]}}}